ICONICS > 实例探究 > Customer Success Story: CSL Behring and CSL Limited

Customer Success Story: CSL Behring and CSL Limited

ICONICS Logo
公司规模
1,000+
地区
  • Europe
国家
  • Germany
产品
  • GENESIS32 software suite
  • DataWorX™32
  • TrendWorX™32
  • WebHMI™
  • AlarmWorX™32
技术栈
  • Windows Server 2003
  • SQL Server 2005
  • Kepware OPC servers
实施规模
  • Enterprise-wide Deployment
影响指标
  • Brand Awareness
  • Productivity Improvements
技术
  • 分析与建模 - 实时分析
  • 应用基础设施与中间件 - 数据交换与集成
适用行业
  • 医疗保健和医院
  • 药品
适用功能
  • 离散制造
  • 质量保证
用例
  • 过程控制与优化
  • 资产跟踪
服务
  • 软件设计与工程服务
  • 系统集成
关于客户
CSL Behring, a subsidiary of CSL Limited since 2004, traces its corporate roots to Emil von Behring, the first Nobel Prize recipient for Medicine and Physiology in 1901. As a pioneer in the field of immunology, Behring’s ground-breaking work resulted in the development of vaccinations against diphtheria and tetanus. CSL Biotherapies, also a subsidiary of CSL, operates some of the world’s largest flu vaccine manufacturing facilities for the global market. With more than 80 years of experience in the development and manufacturing of vaccines, and nearly 40 years with flu vaccines, CSL is committed to reliability, safety and quality. Following the June 2009 World Health Organization announcement of an influenza pandemic, CSL developed a pandemic vaccine (H1N1) and signed a 180 million dollar contract with the US Department of Health and Human Services (HHS) to provide bulk H1N1 influenza antigen.
挑战
CSL Behring, a subsidiary of CSL Limited, is a pioneer in the field of immunology and operates some of the world’s largest flu vaccine manufacturing facilities. In 2009, following the announcement of an influenza pandemic by the World Health Organization, CSL developed a pandemic vaccine (H1N1) and signed a 180 million dollar contract with the US Department of Health and Human Services (HHS) to provide bulk H1N1 influenza antigen. The challenge was to ensure rapid and safe production of the H1N1 flu vaccine for the US market in CSL Behring’s FDA-approved filing and packaging facility in Marburg, Germany. The company needed a system where production data could be logged reliably and stored safely, meeting the recording requirements of the FDA, specifically the 21 CFR Part 11, which outlines the controls necessary for the regulated industry to utilize electronic records and electronic signatures.
解决方案
ICONICS’ GENESIS32 software suite was deployed to enable rapid and safe production of the H1N1 flu vaccine. The suite includes DataWorX™32, TrendWorX™32, WebHMI™, AlarmWorX™32 and ICONICS OPC DataStore, which combine to create the solution bridging the gap between industrial automation and the medical field. The H1N1 vaccine is dispensed into single use syringes or multi-dose vials in a sterile conveyor line, and then packaged and sent to CSL’s Illinois site for distribution across the US. TrendWorX32 facilitates enterprise-wide data collection, logging, charting, reporting and analysis. A DataStore OPC Server stores collected information from proximity sensors, such as bottles in and out, rejects, and total production counts. AlarmWorX32 improves CSL’s ability to identify, quickly respond to and to document abnormal conditions throughout the bottling process. Internet and Intranet connectivity is provided to GENESIS32 applications securely through WebHMI.
运营影响
  • Efficient and safe bottling methods are afforded by ICONICS industrial automation solution.
  • The solution enables CSL to meet the recording requirements of the FDA, specifically the 21 CFR Part 11.
  • The system allows for reliable logging and safe storage of production data.
  • The solution improves CSL’s ability to identify, quickly respond to and to document abnormal conditions throughout the bottling process.
数量效益
  • The total amounts of users who can use the system simultaneously are 109.

Case Study missing?

Start adding your own!

Register with your work email and create a new case study profile for your business.

Add New Record

相关案例.

联系我们

欢迎与我们交流!
* Required
* Required
* Required
* Invalid email address
提交此表单,即表示您同意 IoT ONE 可以与您联系并分享洞察和营销信息。
不,谢谢,我不想收到来自 IoT ONE 的任何营销电子邮件。
提交

感谢您的信息!
我们会很快与你取得联系。